

12  
#19C  
Dra  
1/22/02

# Clark & Elbing LLP

176 Federal Street  
Boston, MA 02110-2214

Telephone 617-418-0200  
Facsimile 617-418-7045  
617-418-7046

FAX RECEIVED

JAN 18 2001

GROUP 1600

OFFICIAL

**Date:** January 17, 2002

**To:** Examiner Anne-Marie Baker  
U.S. Patent and Trademark Office  
Group Art Unit 1632

**Facsimile:** (703) 308-4556  
(703) 305-3592

**From:** Paul T. Clark

**Re:** U.S. Application No. 09/040,518  
"Production of Biofilaments in Transgenic Animals"  
Attorney Docket No: 06632/011001

**Pages:** 23, including this one

**Message:**

NOTICE: This facsimile transmission may contain confidential or privileged information intended for the addressee only. If you are not the addressee, be aware that any disclosure, copying, distribution, or use of the information is prohibited. If you have received this facsimile transmission in error, please call us at 617-428-0200 to arrange for its return at no cost to you.

PATENT  
ATTORNEY DOCKET NO. 06632/011001

Certificate of Transmission: Date of Transmission: <u>1/17/02</u>	
I hereby certify under 37 CFR 1.8 that this correspondence is being sent by Facsimile to Examiner Baker of the United States Patent Office in Washington, D.C. at Facsimile No. 703-308-4556 or 703-305-3592	
<u>Christine M. Citro</u>	<u>Christine M. Citro</u>
Printed name of person faxing correspondence	Signature of person faxing correspondence

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Costas N. Karatzas et al.	Art Unit:	1632
Serial No.:	09/040,518	Examiner:	Anne-Marie Baker
Filed:	March 17, 1998	Customer No.:	21559
Title:	PRODUCTION OF BIOFILAMENTS IN TRANSGENIC ANIMALS		

Assistant Commissioner for Patents  
Washington, D.C. 20231

REPLY TO EXAMINER'S ACTION

In reply to the Examiner's Action mailed in the above-captioned case on July 18, 2001, Applicants submit the following amendments and remarks.

AMENDMENTSIn the Claims:

Kindly amend claims 5 and 13 to read as follows.

5. (Twice Amended) A non-human transgenic mammal in which the genome of cells that contribute to urine production in said mammal comprises the nucleic acid molecule of claim 1, wherein said promoter is urine-producing cell-specific, and wherein